Pliant Therapeutics Advances in Clinical Trials and Oncology Research: A Promising Outlook for PLRX Stock
ByAinvest
Thursday, May 8, 2025 5:32 pm ET1min read
PLRX--
TOI--
Pliant Therapeutics (PLRX) is advancing in clinical trials and oncology research, with key data from the BEACON-IPF trial expected in Q1. The company has also reported promising antitumor effects in a Phase 1 dose escalation study of PLN-101095. Analysts forecast an average target price of $4.79, with a high estimate of $17.00 and a low estimate of $1.50, indicating a potential upside of 227.79% from the current price of $1.46. The average brokerage recommendation is currently 2.8, indicating a "Hold" status.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet